Prenatal Corticosteroids and Antioxidants in Preterm Infants (RESOX)
Premature infants are highly susceptible to oxidative stress because of the immaturity of their antioxidant defense system. The use of prenatal glucocorticosteroids administered to the mother improves respiratory function and overall outcome. The investigators hypothesize that prenatal glucocorticosteroids favor the expression and competence of the antioxidant defense system.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Prenatal Corticosteroids Enhance the Antioxidant Defense System in Extremely Low Gestational Age Neonates|
- Evaluation of glutathione redox status in cord blood. [ Time Frame: at birth ] [ Designated as safety issue: No ]
- Evaluation of antioxidant activity. [ Time Frame: at birth ] [ Designated as safety issue: No ]
|Study Start Date:||January 2003|
|Study Completion Date:||January 2005|
|Primary Completion Date:||January 2005 (Final data collection date for primary outcome measure)|
Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
NON PRENATAL CORTICOSTEROIDS
Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
This is an observational study recruiting extremely low gestational age neonates (<28 weeks gestation) whose mothers received or not full scheduled prenatal glucocorticosteroids. Healthy term newly born infants acted as controls.
At birth cord blood were drawn for the following analytical determinations: reduced and oxidized glutathione; malondialdehyde; superoxide dismutase; catalase; glutathione peroxidase; glutathione reductase; glutathione s-transferase. In addition, first urine voided was collected for ortho-tyrosine/phenylalanine and 8-hydroxy-2-oxo-deoxyguanosine/2-deoxyguanosine determination. Analytical data and clinical outcomes are compared.
|Division of Neonatology; University Hospital La Fe|
|Valencia, Spain, 46009|
|Principal Investigator:||MAXIMO VENTO, PHD, MD||Valencian Agency of Health|